重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用

BACKGROUND AND OBJECTIVE: Squamous cell carcinoma (SCC) is a common pathological type of nonsmall cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients' survival time. Te aim of the study was to analyze the efcacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC. METHODS: We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed. RESULTS: Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progressive disease in 2 patients (14.3%). Te objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. Te median progression-free survival (PFS) was 9.3 months. Te main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomiting (1/15, 6.7%). CONCLUSION: Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.